Bioxcel Therapeutics Share Price Today: Live Updates & Key Insights
Bioxcel Therapeutics share price today is $0.868, up -2.62%. The stock opened at $0.8681 against the previous close of $0.8703, with an intraday high of $0.87 and low of $0.8334.
Bioxcel Therapeutics Share Price Chart
Bioxcel Therapeutics
Bioxcel Therapeutics Share Price Performance
Bioxcel Therapeutics Institutional Holdings
Bioxcel Therapeutics Market Status
Bioxcel Therapeutics Fundamentals
Market Cap 26.87 M
PB Ratio 27.5004
PE Ratio 0.0
Enterprise Value 110.28 M
Total Assets 44.92 M
Volume 259111
Bioxcel Therapeutics Company Financials
About Bioxcel Therapeutics & investment objective
Company Information BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Organisation Drug Manufacturers - Specialty & Generic
Employees 29
Industry Drug Manufacturers - Specialty & Generic
CEO Dr. Vimal D. Mehta Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Bioxcel Therapeutics FAQs
What is the share price of Bioxcel Therapeutics today?
The current share price of Bioxcel Therapeutics is $0.868.
Can I buy Bioxcel Therapeutics shares in India?
Yes, Indian investors can buy Bioxcel Therapeutics shares by opening an international trading and demat account with Motilal Oswal.
How to buy Bioxcel Therapeutics shares in India?
You can easily invest in Bioxcel Therapeutics shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Bioxcel Therapeutics shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Bioxcel Therapeutics.
Can I buy fractional shares of Bioxcel Therapeutics?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Bioxcel Therapeutics?
Bioxcel Therapeutics has a market cap of $26.87 M.
In which sector does Bioxcel Therapeutics belong?
Bioxcel Therapeutics operates in the Drug Manufacturers - Specialty & Generic sector.
What documents are required to invest in Bioxcel Therapeutics stocks?
To invest, you typically need:
What is the PE and PB ratio of Bioxcel Therapeutics?
The PE ratio of Bioxcel Therapeutics is N/A and the PB ratio is 27.50.